Silvia Segovia Chacón

ORCID: 0000-0003-0210-5829
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pregnancy and Medication Impact
  • Pregnancy and preeclampsia studies
  • Maternal and fetal healthcare
  • Gestational Diabetes Research and Management
  • Gestational Trophoblastic Disease Studies
  • Folate and B Vitamins Research
  • Pharmaceutical studies and practices
  • Ectopic Pregnancy Diagnosis and Management
  • Reproductive Health and Contraception
  • Child and Adolescent Health

Karolinska Institutet
2021-2023

Community Link
2022

In observational medication pregnancy safety studies, children are often followed from birth to 1 year of age. However, some major congenital malformations (MCM) may take longer diagnose.

10.1111/ppe.13011 article EN cc-by Paediatric and Perinatal Epidemiology 2023-10-11

To estimate the incidence rates for ectopic pregnancy by contraceptive method in a cohort of women using hormonal contraception Sweden between 2005 and 2016.Women aged 15-49 years with filled prescription Swedish Prescribed Drug Register 2016 were included. For each woman, all exposed woman-years allocated to treatment episodes depending on contraception. Treatment time started day was ended first end supply, new eligible dispensing, pregnancy-related diagnosis its associated estimated last...

10.1097/aog.0000000000004726 article EN cc-by-nc-nd Obstetrics and Gynecology 2022-04-05

Introduction Inconsistent results have been reported on the association between folic acid use in pregnancy and risk of GDM. The aim this study was to estimate GDM two population-based Nordic cohorts. Material methods Two cohort studies were conducted using data from national population registers Norway (2005–2018, n = 791,709) Sweden (2006–2016, 1,112,817). Logistic regression used associations self-reported prescribed use, compared non-users, adjusting for covariates. To quantify how...

10.1371/journal.pone.0272046 article EN cc-by PLoS ONE 2022-08-11

Abstract Introduction For phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, the only approved indication in women is for pulmonary arterial hypertension. These drugs are increasingly being proposed and tested treatment of female infertility complications pregnancy. However, extent use PDE5 inhibitors general pregnant population over last decades unknown. Therefore, we conducted a descriptive cohort study using data from health registers Scandinavian countries. Material methods...

10.1111/aogs.14251 article EN cc-by-nc Acta Obstetricia Et Gynecologica Scandinavica 2021-08-28
Coming Soon ...